Skip to main content

Regeneron Is the Stock to Watch on Booster Approval: Jim Cramer

Publish date:
Video Rating:
Video Duration:

The Centers for Disease Control and Prevention gave final approval to begin administering booster shots of Pfizer's  (PFE) - Get Free Report and Moderna's  (MRNA) - Get Free Report COVID vaccine for immunocompromised people Friday, following a unanimous endorsement from the Advisory Committee on Immunization Practices.  

The recommendation is for Pfizer recipients 12 years and older and Moderna recipients 18 years and older. 

In a written statement endorsing the vaccine, CDC Director Dr. Rochelle Walensky said emerging data suggests fully-vaccinated immunocompromised people do not build the same level of immunity as fully-vaccinated people who are not immunocompromised:

"While people who are immunocompromised make up about 3% of the U.S. adult population, they are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness. Included in CDC’s recommendation are people with a range of conditions, such as recipients of organ or stem cell transplants, people with advanced or untreated HIV infection, active recipients of treatment for cancer, people who are taking some medications that weaken the immune system, and others. A full list of conditions can be found on CDC’s website. The additional dose of an mRNA COVID-19 vaccine should be the same vaccine as the initial series and administered at least four weeks after completing a primary mRNA COVID-19 vaccine series. While vaccination is likely to increase protection in this population, even after vaccination, people who are immunocompromised should continue follow current prevention measures (including wearing a mask, staying 6 feet apart from others they do not live with, and avoiding crowds and poorly ventilated indoor spaces) to protect themselves and those around them against COVID-19 until advised otherwise by their healthcare provider. CDC does not recommend additional doses or booster shots for any other population at this time."

The CDC approval followed the Food and Drug Administration approval of a third shot of the coronavirus vaccine for immunocompromised people late Thursday. 

In this video taped August 12 ahead of Thursday's FDA approval, Jim Cramer told Action Alerts PLUS senior analyst Jeff Marks that Pfizer PFE and Moderna MRNA will benefit from the news, but it was Regeneron  (REGN) - Get Free Report that caught his attention. 

Watch his full take in the video above. 

Related Videos